Merck has been a money-making machine for decades, but it faces growing competition and patent expirations. Will this drug giant prevail? Read More

Pfizer is a growth-and-income stock found in many retirement portfolios. But is the competition from biotech "disruptors" getting too hot for this Big Pharma stalwart? Read More

Chevron is poised to gain from rising crude prices, but the energy sector remains volatile. Can this "super major" overcome the industry's uncertainties? Read More

As the largest health insurer in the U.S., UnitedHealth Group is poised to greatly benefit from booming health care expenditures. But do proposed government policy changes threaten the stock? Read More

Health services giant Johnson & Johnson has been a reliable growth-and-income stock for years, but can it overcome the scandal about its allegedly carcinogenic talcum powder? Read More

As it meets the booming demand for enterprise cloud solutions, this large-cap software vendor has seen its stock soar. But rising global pressures could undermine Workday's momentum. Read More

Cryptocurrencies are volatile, posting extreme fluctuations in value. Is cryptocurrency Litecoin an exciting investment opportunity or a lot of hokum? Read More

This maker of cloud, networking and cybersecurity software has seen its stock consistently crush the market. Will the good times continue or is VMware due for a breather? Read More

Can beleaguered Taronis change direction in 2019 and dominate the biofuel market, now that it has a new name, a new strategy and even a new ticker symbol? Read More

Schlumberger is a leading oilfield services company with a global reach, but falling oil prices have weighed on the stock. Can Schlumberger come back? Read More